Peter Marks
Peter Marks, MD, PhD is the director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA). The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies.
Peter Marks, MD, PhD is the director of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA).
The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies.
See more
The center is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies.
Articles: Peter Marks
US FDA’s Efforts to Advance the Development of Gene Therapy
USA / Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene therapies in the US and beyond. To keep pace with the remarkable and continuing growth of gene therapy, FDA’s Center for Biologics Evaluation and…
Latest Report
